ACP
BCAB icon

Acuta Capital Partners’s BioAtla BCAB Stock Holding History

Acuta Capital Partners’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$4.13M – 37
2022
Q4 		$4.13M Sell
10,000
-400
-4% -$166K 2.54% 17
2022
Q3 		$4M Buy
+10,400
New +$3.4M 1.72% 19

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acuta Capital Partners's BCAB Position: Q1 2023 in Review

Acuta Capital Partners sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 10,000 shares — an estimated $4.13M sold.

Acuta Capital Partners first reported a position in BCAB in Q3 2022 and held it in 2 quarters. The position peaked at $4.13M in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

  • Acuta Capital Partners reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 10,000 BioAtla shares in Q1 2023, an estimated $4.13M.
  • Acuta Capital Partners first reported a position in BioAtla in Q3 2022 and held it in 2 quarters.
  • Acuta Capital Partners's BioAtla position peaked at $4.13M in Q4 2022.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on Acuta Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.